Evidence map›Paper›PMID 39243175›Full record

Observational studyJournal of diabetes investigation2024

Adherence and treatment discontinuation of oral semaglutide and once-weekly semaglutide injection at 12 month follow-up: Japanese real-world data.

Takeshi Horii, Chikako Masudo, Yui Takayanagi, Yoichi Oikawa, Akira Shimada, Kiyoshi Mihara

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of diabetes investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takeshi Horii *Department of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-5465-4531
Chikako Masudo *Department of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.
Yui TakayanagiDepartment of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.
Yoichi OikawaDepartment of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0003-1524-6751
Akira ShimadaDepartment of Endocrinology and Diabetes, School of Medicine, Saitama Medical University, Saitama, Japan.ORCID https://orcid.org/0000-0002-3954-4983
Kiyoshi MiharaDepartment of Pharmacy, Faculty of Pharmacy, Musashino University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adherence and treatment continuation rates of the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide for both oral (O-SEMA) and subcutaneous injection (SEMA-SC) remain unknown in real-world clinical practice. This retrospective observational study compared the 12 month adherence and treatment discontinuation of O-SEMA and once-weekly SEMA-SC in patients with type 2 diabetes using a real-world claims database. SEMA-SC initiators were 1:1 propensity score-matched to O-SEMA initiators. Non-adherence was defined as <0.8 of the proportion of days covered. SEMA-SC had a significantly higher odds ratio (OR) for non-adherence than O-SEMA (OR: 1.39). The hazard ratio for treatment discontinuation, using O-SEMA as the reference, was 1.45 for SEMA-SC, although the discontinuation rate of O-SEMA was higher during the early stage. O-SEMA initiators showed significantly higher adherence and greater persistence in therapy than SEMA-SC initiators at 12 months, which could lead to earlier initiation of GLP-1RA treatment.

Indexed as

Diabetes Mellitus, Type 2Drug MonitoringGlucagon-Like PeptidesHypoglycemic AgentsAdministration, OralAgedEast Asian PeopleFemaleFollow-Up StudiesGlucagon-Like Peptide-1 Receptor AgonistsHumansInjections, SubcutaneousJapanMaleMiddle AgedRetrospective StudiesGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsSemaglutideInjectionOralSemaglutide

Identifiers

PMID39243175
PMCPMC11527826

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.